Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

Juliana Park,Sophia Archuleta,May-Lin Helen Oh,Lynette Pei-Chi Shek,Jing Jin,Matthew Bonaparte,Carina Fargo,Alain Bouckenooghe

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

2019

Juliana Park
Sophia Archuleta
May-Lin Helen Oh
Lynette Pei-Chi Shek
Jing Jin
Matthew Bonaparte
Carina Fargo
Alain Bouckenooghe

ABSTRACTThe tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Lati...

Keywords:

Pediatrics
Immunogenicity
Dengue fever
Placebo-controlled study
Immunology
Booster dose
Booster (rocketry)
Medicine
Dengue vaccine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations